Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin versus heparin in atrial fibrillation with NSTE-ACS undergoing PCI
ChiCTR2000038371Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of bivalirudin and heparin in acute coronary syndrome (ACS) and Atrial fibrillation (AFib) (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Major bleeding. Started Aug 2020; status: recruiting.
02
Drugs
bivalirudinheparin
03
Conditions
acute coronary syndrome (ACS)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2000038371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038371.